What’s Occurring With Novo Nordisk Inventory?

Novo Nordisk ADR (NYSE: NVO) at the moment trades at $85 per share, greater than 40% beneath its peak stage of over $145 seen in June of this 12 months. In distinction, its closest peer, Eli Lilly stock (NYSE:LLY) is down 15% over this era. NVO inventory was buying and selling round $55 in early June 2022, simply earlier than the U.S. Fed began growing charges, and is now 55% above that stage, in comparison with 45% positive factors for the S&P 500 throughout this era. This outperformance of NVO inventory may be attributed to a ramp up in gross sales of its weight problems medicine. Novo Nordisk relies out of Denmark. Notably, Denmark’s rates of interest are decrease than these within the U.S.

NVO inventory has struggled previously few months. Actually, Novo was down over 20% on Friday, December 20, after the corporate reported underwhelming outcomes from a late-stage scientific examine for its weight problems remedy – CagriSema. The trial confirmed that CagriSema helped sufferers scale back their weight by 22.7%, beneath the 25% Novo Nordisk was concentrating on. However, even earlier than this fall, the inventory was underperforming, with slower than anticipated gross sales progress for its weight problems medicine. Actually, the corporate missed Q3 income and earnings estimates, weighing on its inventory. Whereas NVO inventory has had a tricky trip these days, if you would like upside with a smoother trip than a person inventory, take into account the High-Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.

On this word, we seize developments within the firm’s inventory in the course of the turbulent market situations seen over 2022. It compares these developments to the inventory’s efficiency in the course of the 2008 recession.

2022 Inflation Shock

• 2020 – early 2021: Enhance in cash provide to cushion the influence of lockdowns led to excessive demand for items; producers unable to match up.
• Early 2021: Delivery snarls and employee shortages from the coronavirus pandemic proceed to harm provide.
• April 2021: Inflation charges cross 4% and enhance quickly.
• Early 2022: Vitality and meals costs spike as a result of Russian invasion of Ukraine. Fed begins its charge hike course of.
• June 2022: Inflation ranges peak at 9% – the very best stage in 40 years. The S&P 500 index declined greater than 20% from peak ranges.
• July – September 2022: Fed hikes rates of interest aggressively – leading to an preliminary restoration within the S&P 500 adopted by one other sharp decline.

• October 2022 – July 2023: Fed continues charge hike course of; enhancing market sentiments helps S&P500 recoup a few of its losses.

• August 2023 – August 2024: Fed has saved rates of interest unchanged to quell fears of a recession and maintain inflation in test
• Since September 2023: Fed minimize charges by 100 bps, however turned hawkish for its 2025 outlook

In distinction, right here’s how NVO inventory and the broader market carried out in the course of the 2007/2008 disaster.

Timeline of 2007-08 Disaster

• 10/1/2007: Approximate pre-crisis peak in S&P 500 index
• 9/1/2008 – 10/1/2008: Accelerated market decline comparable to Lehman chapter submitting (9/15/08)
• 3/1/2009: Approximate bottoming out of S&P 500 index
• 12/31/2009: Preliminary restoration to ranges earlier than accelerated decline (round 9/1/2008)

Novo Nordisk and S&P 500 Efficiency Throughout 2007-08 Disaster

NVO inventory declined from practically $5.40 in April 2008 (pre-crisis peak for the inventory) to $3.20 in early March 2009 (because the markets bottomed out), implying it misplaced 40% of its pre-crisis worth. It recovered publish the 2008 disaster to ranges of round $5 in early 2010, rising about 56% between March 2009 and January 2010. The S&P 500 Index noticed a decline of 51%, falling from ranges of 1,540 in September 2007 to 757 in March 2009. It then rallied 48% between March 2009 and January 2010 to succeed in ranges of 1,124.

Novo Nordisk’s Fundamentals Over Latest Years

Novo Nordisk’s income rose over 2x from 127 billion DKK in 2020 to 271 billion DKK for the final twelve-month interval. This will primarily be attributed to the success of its diabetes and weight problems medicine – Wegovy and Ozempic. Whereas Ozempic’s gross sales have risen 4.5x from $21.2 billion DKK in 2020 to 95.7 billion DKK in 2023, Wegovy’s gross sales have surged to $31.3 billion in 2023, since its launch in 2021.

The corporate’s working margin has additionally expanded from 42.6% to 43.7% over the identical interval. Greater revenues and margin enlargement resulted within the backside line of 21.20 DKK per share for the final twelve month interval, versus 9.01 DKK per share in 2020.

Does Novo Nordisk Have A Enough Money Cushion To Meet Its Obligations By means of The Ongoing, Unsure Charge Minimize Cycle?

Novo Nordisk’s whole debt elevated from 10 billion DKK in 2020 to 57 billion DKK now, whereas its money elevated from round 13 billion DKK to 75 billion DKK over the identical interval. The corporate additionally garnered 118 billion DKK in money flows from operations within the final twelve months. Novo Nordisk is a web debt constructive firm, and it has a enough money cushion to satisfy its near-term obligations.

Conclusion

Whereas the Fed’s efforts to tame runaway inflation charges has helped market sentiments previously, its current hawkish outlook for 2025 is now worrying traders. We consider Novo Nordisk inventory has the potential for some positive factors as soon as markets finds a footing, digesting the information of fewer than anticipated charge cuts subsequent 12 months. Though the event round CagriSema doesn’t bode properly for NVO inventory, we predict after a significant 40% correction from its current highs, the headwinds look like priced in. Notably, the $123 common of analysts worth estimates displays a stable 45% upside potential from right here.

Admirably, NVO inventory has generated higher returns than the broader market in every of the final three years. Returns for the inventory had been 63% in 2021, 23% in 2022, and 55% in 2023. Equally, the Trefis High Quality (HQ) Portfolio, with a group of 30 shares, is much less unstable. And it has outperformed the S&P 500 annually over the identical interval. Why is that? As a bunch, HQ Portfolio shares offered higher returns with much less threat versus the benchmark index; much less of a roller-coaster trip, as evident in HQ Portfolio efficiency metrics.

Whereas NVO inventory seems to be prefer it has some room for progress, it’s useful to see how a few of its friends, resembling Eli Lilly, fare on metrics that matter. You will see that different useful comparisons for corporations throughout industries at Peer Comparisons.

[1] Returns as of 12/22/2024
[2] Cumulative whole returns because the finish of 2016

Make investments with Trefis Market-Beating Portfolios
See all Trefis Price Estimates

The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.